12707 HIGH BLUFF DRIVE, SAN DIEGO, CA
CFO Retention Bonus Agreement - Nelson Sun to Receive $346,500
Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical Hold
Reports First Quarter 2026 Financial Results and Provides Business Updates
Financial Results, Press Release
Announces Voluntary Pause of Phase 3 HERO Trial in Prader-Willi Syndrome
Announces Leadership Appointments
Announces FDA Submission and IRB Approval of Amended Trial Protocol for Lead Candidate ARD-101, Expanding Eligibility in Phase 3 Study of Prader-Willi Syndrome
Investor Presentation
Q1
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities to be Offered to Employees
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(4)
PRE 14A
Statement of Changes in Beneficial Ownership